GlobeNewsWire
06 Dec 2025, 13:30 UTC · 42w ago
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Verdict
Headline takes no side. We score ADPT +0.80 — strongly bullish.
- Expected · ADPT
+0.80strongly bullish
−1 bearish0bullish +1More positive than 88% of ticker scores this week



